Aug 16 2006
MIV Therapeutics will present development progress of the Company's Hydroxyapatite (HAp) coatings for coronary stents and other devices at the 19th International Symposium on Ceramics in Medicine conference in Chengdu, China.
Dr. Quanzu Yang, PhD, from MIVT research partner University of British Columbia, will address the international body of biomaterials scientists and industry leaders to discuss recent research developments. Dr. Yang will discuss data regarding the long-term biocompatibility and other advantages of the Company's patented technology for deposition of HAp coatings and encapsulation of drugs in the HAp coatings.
"The microporous ultra-thin HAp coating with a potential for drug elution shows excellent promise for long-term biocompatibility, and makes an attractive candidate for next-generation stent coating," said Dr. Yang, "It's an honor to present our work with HAp and I look forward to discussing these and other findings with our colleagues in China. Our newest, polymer-free technology for drug encapsulation in HAp coatings shows the potential to revolutionize the industry of medical devices with drug delivery capabilities"
The conference will focus on bioceramics, such as calcium phosphates and hydroxyapatite technology; an indispensable biomaterials in clinical practice. The annual conference will concentrate on new challenges being faced in the bioceramics industry from the progress of modern medicine. It will provide a multi-disciplinary platform for Biomaterials, Scientists, Researchers, Engineers, Manufacturers, Dentists and Surgeons to share their latest achievements and encourage important discussion for next breakthroughs in the field.
Based on bioceramics technology, MIVT's HAp coatings are designed to substantially improve the safety and long-term performance of vascular stents because they do not trigger adverse reactions of the body's immune system commonly associated with existing stent technology. Such complications include inflammation, creation of thrombus (blood clots) and, importantly, re-narrowing of arteries due to endothelial tissue re-growth inside blood vessels in the area of newly implanted stents.
During the presentation, MIVT will also report on the progress of development of novel HAp coatings for implants, such as hip or knee implants, developed under the collaborative research and development program between the University of British Columbia and MIVT. Research has been focused on wet chemical technologies for ultra-thin and micro-thin calcium-phosphate based bio-ceramic films. The ultra-thin films have been designated as a surface modification of metallic implants, where the micro-thin films are evaluated as a potential vehicle for drug delivery purposes for implantable medical devices.
http://www.mivtherapeutics.com/